Espinach RM

Idioma: Español
Referencias bibliográficas: 28
Paginas: 87-92
Archivo PDF: 231.49 Kb.

FRAGMENTO

INTRODUCCIÓN Se quiere compartir la historia de un paciente masculino de 52 años que desarrolló enfermedad renal crónica a causa de una glomerulonefritis crónica no determinada. Para el año 2004 se le realizó trasplante renal de donador cadavérico. El paciente tenía un buen apego al tratamiento, sin embargo evolucionó con un deterioro progresivo de la función renal del injerto después de los 8 años de su trasplante, por lo que se consideró que fue producto de toxicidad por el inhibidor de calcineurina, del régimen inmunosupresor que utilizaba.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Jaffe JA Liftman C Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis. 2005;46(2):316-319.

2. Humpfner A Hummel S Schultz W. Diagnosis and therapeutic approaches to aluminum overload in dialyzed patients-- representative study questionnaire in West German dialysis units in 1989-1990. Nephrol Dial Transplant. 1993;8:S51-S54.

3. Salusky IB. A new era in phosphate binder therapy: What are the options? Kidney Int. 2006;105:S10-S15.

4. Fernández-Martin JL Canteros A Serrano M Gonzalez-Carcedo A Díaz-Corte C Cannata, JB. Prevention of aluminum exposure through dialysis fluids. Analysis of changes in the last 8 years. Nephrol Dial Transplant. 1998;13: S78–S81.

5. Savory J Berlin A Courtoux C Yeoman B Wills M. Summary report of an international workshop on “The role of biological monitoring in the prevention of aluminum toxicity in man: Aluminum analysis in biological fluids.” Ann Clin Lab. 1989;13: 444-451.

6. Slatopolsky E. The interaction of parathyroid hormone and aluminum in renal osteodystrophy. Kidney Int. 1987;31(3):842- 854.

7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S108- S122.

8. Koiwa F Sato Y. Chemistry and history of phosphate binder. Clin Calcium. 2009;19: 198-204.

9. Jaffe JA Liftman C Glickman JD. Frequency of elevated serum aluminum levels in adult dialysis patients. Am J Kidney Dis. 2005;46 (2):316-319.

10. Kan WC Chien CC Wu CC Su SB Hwang JC Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010;25(5):1604- 1608.

11. Berlyne GM Pest D Ben-Ari J et al. Hyperaluminaemia from aluminum resins in renal failure. Lancet. 1970;296(7671):494– 496.

12. Sherrard DJ. Letter: the myth of aluminum toxicity. N Engl J Med. 1974;290:750.

13. Wei-Chih K Chih-Chiang Ch Yi-Hua L Jyh- Chang H Shih-Bin S Hsien-Yi W. Aluminum Overload: An Easily - Ignored Problem in Dialysis Patients with Hyperparathyroidism. ISBN: 978-953-51-0478-0, InTech, Available from: http://www.intechopen.com/books/hyperparat hyroidism/aluminum-overload-an-easilyignored- problem-in-dialysis-patients-withhyperparathyroidism

14. Alfrey AC. Aluminum toxicity in patients with chronic renal failure. Ther Drug Monit. 1993;15(6):593-597.

15. Alfrey AC LeGendre GR Kaehny WD. The dialysis encephalopathy syndrome: Possible aluminum intoxication. N Engl J Med. 1976;294(4):184-188.

16. House RA. Factors affecting plasma aluminum concentrations in nonexposed workers. J Occup Med. 1992;34:1013-1017.

17. U.S. department of Health and Human Services. Public Health Service Agency for Toxic Substances and Disease Registry. Toxicological profile for aluminum. September 2008.

18. Cannata JB Fernández-Soto I Fernández- Menéndez MJ et al. Role of iron metabolism in absorption and cellular uptake of aluminum. Kidney Int.1991;39(4):799–803.

19. Losekann A Ureña P Khiraoui F et al. Aluminium intoxication in the rat induces partial resistan e to the effect of recombinant human erythropoietin. Nephrol Dial Transplant. 1990;5(4):258–263.

20. Drüeke TB. Resistance to recombinant human erythropoietin in hemodialysis patients. Am J Nephrol. 1990;10(2):S34–S39.

21. Malluche H. Aluminum and bone disease in chronic renal failure. Nephrol Dial Trasplant. 2002;17(2):S21-S24.

22. Norris KC Crooks PW Nebeker HG et al. (1985). Clinical and laboratory features of aluminum-related bone disease: Differences between sporadic and “epidemic” forms of the syndrome. Am J Kidney Dis. 1985;6:342- 347.

23. Diaz-Corte C Fernandez Martin JL. Effect of aluminium load on parathyroid hormone synthesis. Nephrol Dial Trasplant. 2001;16: 742-745.

24. Andreoli SP Bergstein JM Sherrard DJ. Aluminum intoxication from aluminumcontaining phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med. 1984;310:1079-1084.

25. Brem AS DiMario C Levy DL. Perceived Aluminum-Related Disease in a Dialysis Population A Report From the End-Stage Renal Disease Network 28. Arch Intern Med. 1989;149:2541-2544.

26. McCauley J Sorkin MI. Exacerbation of aluminum encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant. 1989;4(2):110-114.

27. Bene C Manzler A Bene D Kranias G. Irreversible ocular toxicity from single “challenge” dose of deferoxamine. Clin Nephrol. 1989;31(1):45-48.

28. Kan WC Chien CC Wu CC Su SB Hwang JC Wang HY. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients. Nephrol Dial Transplant. 2010;25(5):1604- 1608.